We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alzheimer Patients and the Snoezelen Program

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00548951
Recruitment Status : Completed
First Posted : October 24, 2007
Last Update Posted : December 16, 2015
Sponsor:
Information provided by (Responsible Party):
Dr. Roumen Milev, Queen's University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
To determine the connection between Social Withdrawal and Sensory Deprivation in elderly clients with Alzheimer's Type Dementia (i.e. how providing sensory stimulation might reduce social withdrawal).

Condition or disease Intervention/treatment Phase
Dementia Other: Snoezelen Room Other: Control Phase 1

Detailed Description:

The Snoezelen concept or program was originally thought up in Holland and comes from two Dutch words meaning to "sniff and doze". It was first introduced in the Netherlands in the 1970's. The first room was introduced in Snoezelen examines how a group of people react to an area that is private, relaxed and one that they trust. This program will bring out one's sense of taste, touch, smell, sight and hearing just by being in a specially designed room. Trust and relaxation will be looked at by those people with developmental disabilities (those that learn at a slower rate). Snoezelen originated with the belief that everyone needs nerve pulses (senses).

Inside a Snoezelen room you will find, dimmed lights, a relaxed atmosphere and pleasant surroundings, soothing sounds, intriguing aromas, tasty puddings, candies, interesting light effects (fiber optic light spray), comfortable seating, opportunities for interaction and engagement, sense of control over environment, tactile objects (awareness box), bubble tube, solar projector wheel, water fountain, massage pillow, massage tube, tranquility and solitude. The Snoezelen room is an environment in which the primary senses (see, hear, taste, touch) are stimulated all to create an environment that is both relaxing and stimulating. The benefits of Snoezelen change per person but may include some of the following:

  • Increased resident and caregiver communication
  • Increased awareness and understanding of the environment

The Snoezelen idea: client-controlled, safe comfortable atmosphere and freedom from pressure.

Sensory Deprivation (loss) The average person touches 300 different surfaces every 30 minutes. The average person with a profound disability will likely touch 1-5 surfaces in the same time frame.

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Connection Between Sensory Deprivation and Social Withdrawal in Clients of a Long Term Care Facility Living With Alzheimer's Disease and the Effects of a Snoezelen Program.
Study Start Date : September 2005
Actual Primary Completion Date : December 2006
Actual Study Completion Date : December 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dementia

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: 1
Subject receives Snoezelen sessions once per week.
 Other: Snoezelen Room
Session in a Snoezelen room once per week for 12 weeks
Active Comparator: 2
Subject receives Snoezelen sessions three times per week.
 Other: Snoezelen Room
Session in a Snoezelen room three times per week for 12 weeks
3
Subject receives no sessions per week.
 Other: Control
Receive no sessions in a Snoezelen Room.


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To evaluate improvement of the residents who are given Snoezelen sessions. [ Time Frame: 12 weeks ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Residents living at Rideaucrest Home (Long Term Care Facility in Kingston, Ontario);
  • Residents having a Mini Mental State Exam with a score of 15 to 27 reflecting mild to moderate dementia;
  • Male or female over 65 years of age;
  • Resident who are able to leave the terrace;
  • Resident who are not actively participating in Life Enrichment Programs;
  • Able to provide informed written and signed consent by resident or substitute decision maker.

Exclusion Criteria:

  • Suffering from severe life threatening illness with a reasonable expectation of death within the next six month;
  • Severe mental disorder in the opinion of the investigator (i.e. bipolar, schizophrenia);
  • No recent change in medication(s) during the past four weeks prior to the project;
  • Other non-Alzheimer-Type Dementia;
  • Residents who suffer from Epilepsy.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00548951


Locations
Layout table for location information
Canada, Ontario
Rideaucrest Home
Kingston, Ontario, Canada, K7K 3H6
Sponsors and Collaborators
Queen's University
Investigators
Layout table for investigator information
Principal Investigator: Roumen V. Milev, MD Queen's University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Dr. Roumen Milev, Principal Investigator, Queen's University
ClinicalTrials.gov Identifier: NCT00548951    
Other Study ID Numbers: PSIY-205-05
First Posted: October 24, 2007    Key Record Dates
Last Update Posted: December 16, 2015
Last Verified: December 2015
Keywords provided by Dr. Roumen Milev, Queen's University:
Dementia
Additional relevant MeSH terms:
Layout table for MeSH terms
Dementia
Brain Diseases
Central Nervous System Diseases
 Nervous System Diseases
Neurocognitive Disorders
Mental Disorders